Latest Angiogenesis inhibitor Stories
A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma.
The antiangiogenic drug pazopanib has demonstrated clinically meaningful activity in patients with refractory urothelial cancer.
Persistent protein expression may explain why tumors return after therapy in glioblastoma patients.
Cancer treatments designed to block the growth of blood vessels were found to increase the number of cancer stem cells in breast tumors in mice, suggesting a possible explanation for why these drugs don't lead to longer survival.
Researchers at Linköping University are now launching a plan to effectively treat psoriasis.
Combining the investigational agents REGN910 and aflibercept yielded statistically significant improvements in antitumor effects in animal models compared with either agent alone.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.